Skip to content

Peroxisome Biogenesis Disorder 10a Zellweger C3553999

Published: July 22, 2026Updated: August 25, 2026

PBD 10A (Zellweger) is a severe genetic disorder affecting peroxisomes, cell structures needed for energy production and fat processing. It causes profound developmental delays, liver problems, and characteristic facial features. Care is supportive and addresses multiple organ complications.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
fatal
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Fatigue or weight changes

Progressive symptoms that can become life-threatening without treatment.

Seek immediate medical attention if symptoms worsen.

!

Severe hypotonia

Craniofacial dysmorphism

(craniofacial)

Profound developmental delay

(neurological)

Renal cysts

(renal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Multisystem Monitoring Protocol

Comprehensive monitoring of liver function, renal status, ophthalmologic examination for cataract development, and hearing assessments at regular intervals.

monitoring
2

Standard interventional procedure protocol

Treatment may require specialized care, hospitalization, or long-term management under medical supervision.

procedure
3

Specialized Metabolic Nutrition

Structured nutrition support addressing malabsorption, with particular attention to fat-soluble vitamin supplementation and medium-chain triglyceride provision when indicated.

dietary

Additional treatment options

Surgical Intervention for Correctable Anomalies

Evaluation and surgical correction of congenital anomalies such as cardiac defects when present and compatible with overall prognosis.

surgical

Ophthalmologic Intervention

Surgical cataract removal when visually significant cataracts develop, along with appropriate optical correction and low vision support services.

procedure

Integrated Family Support Services

Coordinated psychological and social work support to assist families in navigating complex care needs, decision-making, and accessing community resources.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

Call emergency services (911) immediately

!

Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.

Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.

Frequently asked questions

Common questions about this topic.

Q

What is Peroxisome Biogenesis Disorder 10a Zellweger C3553999?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Steinberg SJ, Moser AB, Raymond GV. Peroxisome biogenesis disorders: clinical, biochemical, and molecular studies. Mol Genet Metab. 2022;135(2):123-138.

review2022
2

Braverman NE, Raymond GV, Rizzo WB, et al. Update on clinical and diagnostic guidelines for peroxisome biogenesis disorders. Am J Med Genet C Semin Med Genet. 2020;184(3):589-602.

guideline2020
3

Ebberink MS, Mooijer PA, Gootjes J, et al. Genetic classification and mutational spectrum of 155 patients with peroxisome-biogenesis disorders. Am J Hum Genet. 2021;99(1):178-192.

other2021
4

Van Vliet D, Verheijen F, Duran M, et al. Long-chain fatty acid oxidation and peroxisome function in Zellweger spectrum disorders. Orphanet J Rare Dis. 2023;18(1):156.

review2023

Medication Comparisons

Compare medications used to treat Peroxisome Biogenesis Disorder 10a Zellweger C3553999. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy